Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
New Genomic Data-Sharing Efforts Aim to Bridge Pharma's Revenue-Innovation Gap
May 25, 2011
Efforts spearheaded by Sage Bionetworks and Genetic Alliance hope to encourage drug developers to share precompetitive genomic data from the comparator arms of drug trials and to give study participants more control over their own data generated in clinical investigations.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - Scripps Study Highlights Protein Sulfenylation as Regulator of EGFR Activity, Potential Drug Target
December 16, 2011 / ProteoMonitor - Cellzome Snags More Than $3.1M in Grants for EU-, UK-Sponsored Research Initiatives
December 9, 2011 / ProteoMonitor - As More Patients Gain Knowledge of Genetic Makeup, FDA Warns Against Biased Personalized Rx Trials
November 2, 2011 / Pharmacogenomics Reporter - Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter